BASELINE CARDIOVASCULAR RISK FOR PATIENTS WITH RECENT MYOCARDIAL INFARCTION PRESCRIBED A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR

Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) antibodies significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients uncontrolled with statins and/or ezetimibe. Here we characterize the baseline cardiovascular risk profile in a subset of patients with recent